Fasenra reduced daily rescue medication use by day 3 in patients with severe, uncontrolled asthma with eosinophilic inflammation, according to findings presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
Fasenra (benralizumab, AstraZeneca), a subcutaneous injection, was previously approved by the FDA for additional maintenance treatment of severe eosinophilic asthma in patients older than 12 years.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.